ATE499444T1 - Ein tumorsuppressor mit der bezeichnung ts10q23.3 - Google Patents

Ein tumorsuppressor mit der bezeichnung ts10q23.3

Info

Publication number
ATE499444T1
ATE499444T1 AT98903409T AT98903409T ATE499444T1 AT E499444 T1 ATE499444 T1 AT E499444T1 AT 98903409 T AT98903409 T AT 98903409T AT 98903409 T AT98903409 T AT 98903409T AT E499444 T1 ATE499444 T1 AT E499444T1
Authority
AT
Austria
Prior art keywords
tumor suppressor
suppressor designated
designated
tumor
suppressor
Prior art date
Application number
AT98903409T
Other languages
German (de)
English (en)
Inventor
Peter Steck
Mark Pershouse
Samar Jasser
W Yung
Sean Tavtigian
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE499444(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE499444T1 publication Critical patent/ATE499444T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT98903409T 1997-01-30 1998-01-08 Ein tumorsuppressor mit der bezeichnung ts10q23.3 ATE499444T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3
PCT/US1998/000353 WO1998033907A1 (en) 1997-01-30 1998-01-08 A tumor suppressor designated ts10q23.3

Publications (1)

Publication Number Publication Date
ATE499444T1 true ATE499444T1 (de) 2011-03-15

Family

ID=25152739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98903409T ATE499444T1 (de) 1997-01-30 1998-01-08 Ein tumorsuppressor mit der bezeichnung ts10q23.3

Country Status (14)

Country Link
US (1) US6262242B1 (enExample)
EP (2) EP0972024B2 (enExample)
JP (5) JP2001511002A (enExample)
AR (1) AR011607A1 (enExample)
AT (1) ATE499444T1 (enExample)
AU (1) AU745296B2 (enExample)
CA (1) CA2278849C (enExample)
DE (1) DE69842141D1 (enExample)
DK (1) DK0972024T4 (enExample)
ES (1) ES2361044T5 (enExample)
IL (1) IL131168A0 (enExample)
PT (1) PT972024E (enExample)
WO (1) WO1998033907A1 (enExample)
ZA (1) ZA98756B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
JP4339506B2 (ja) * 1997-08-26 2009-10-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｔｓ１０ｑ２３．３と称する腫瘍抑制因子
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
US7981618B2 (en) * 2003-11-05 2011-07-19 Board Of Regents Of The University Of Texas System Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP3216874A1 (en) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
CN102301002A (zh) * 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和系统
CA2791905A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
EP3572528A1 (en) 2010-09-24 2019-11-27 The Board of Trustees of the Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
US9617601B2 (en) 2011-12-30 2017-04-11 Abbott Molecular Inc. Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
ATE92538T1 (de) 1988-01-21 1993-08-15 Genentech Inc Verstaerkung und nachweis von nukleinsaeuresequenzen.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
JP2000500329A (ja) 1995-10-23 2000-01-18 インペリアル キャンサー リサーチ テクノロジィ リミテッド 癌罹病性の診断およびその治療
JP4339506B2 (ja) * 1997-08-26 2009-10-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｔｓ１０ｑ２３．３と称する腫瘍抑制因子
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
JP5202583B2 (ja) 2013-06-05
JP2010259438A (ja) 2010-11-18
WO1998033907A1 (en) 1998-08-06
US6262242B1 (en) 2001-07-17
CA2278849A1 (en) 1998-08-06
ES2361044T3 (es) 2011-06-13
EP2366712A2 (en) 2011-09-21
JP2014155493A (ja) 2014-08-28
JP2001511002A (ja) 2001-08-07
ZA98756B (en) 1998-08-25
DK0972024T3 (da) 2011-04-26
DE69842141D1 (de) 2011-04-07
EP2366712A3 (en) 2012-11-14
JP4768783B2 (ja) 2011-09-07
IL131168A0 (en) 2001-01-28
EP0972024B2 (en) 2014-06-25
PT972024E (pt) 2011-05-05
ES2361044T5 (es) 2014-10-01
EP0972024B1 (en) 2011-02-23
AU6018998A (en) 1998-08-25
AU745296B2 (en) 2002-03-21
JP2013128485A (ja) 2013-07-04
DK0972024T4 (da) 2014-07-07
AR011607A1 (es) 2000-08-30
JP2009039107A (ja) 2009-02-26
EP0972024A1 (en) 2000-01-19
CA2278849C (en) 2016-04-19

Similar Documents

Publication Publication Date Title
ES1029611Y (es) Un zapato.
NO2006016I1 (no) 7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt) 4,5-diaril-imidazoles 2-substituidos
ATE499444T1 (de) Ein tumorsuppressor mit der bezeichnung ts10q23.3
TR199800818A3 (tr) Ikame edilmis diaminokarbonik asitler.
DE69010536D1 (de) Beschichtete Fugendeckleiste.
DE69836697D1 (de) Neue 3,6-Hemiketale der 9a-Azalidklasse
NO912329L (no) Belegningsanordning.
IT1301914B1 (it) Innesto elettromagnetico.
ZA984085B (en) A novel salt.
TR199700133A2 (tr) Fermuar düzenegi.
FR2690381B1 (fr) Porte-racle.
DK1068200T3 (da) 2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id) Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
FR2699795B1 (fr) Chaussure perfectionnée.
NL1010075A1 (nl) Tuinberging.
FI973505A0 (fi) Korskopplingsapparatandelens trivalent utgaong
ITBO970459A0 (it) Pistola rivettatrice pneumoidraulica perfezionata.
ATA31197A (de) Gewehr
ITTE940003A0 (it) Tricocyn a.c.
ATA132297A (de) Geschütz
ES1034731Y (es) Un reloj-armario.
ITVI940092A0 (it) Pistola volumetrica.
FI3107U1 (fi) Karheeja
ID21318A (id) Turunan-turunan 2,4-diaminopirimidin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0972024

Country of ref document: EP